How to optimize HCV therapy in genotype 4 patients

Liver International

Volumn 33, Issue SUPPL. 1, 2013, Pages 41-45

  Esmat, Gamal ^a,b   El Kassas, Mohamed ^a   Hassany, Mohamed ^a   Gamil, Mohamed Esmat ^a   El Raziky, Maisa ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b NATIONAL HEPATOLOGY AND TROPICAL MEDICINE RESEARCH INSTITUTE   (Egypt)

Author keywords

Genotype 4; Hepatitis C virus; Treatment predictors

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DISEASE SEVERITY; GENETIC POLYMORPHISM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSULIN RESISTANCE; MIXED INFECTION; NONHUMAN; OBESITY; PATIENT COMPLIANCE; PREDICTIVE VALUE; PREVALENCE; PROCESS OPTIMIZATION; REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; PATIENT SELECTION; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RISK ASSESSMENT; RISK FACTORS; SERINE PROTEINASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84872043136     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12059     Document Type: Review

References (45)

1. Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47.
2. McOmish F, Yap PL, Dow BC, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol 1994; 32: 884-92.
3. Esmat G, El Raziky M, El Kassas M, Hassany M, Gamil ME. The future for the treatment of genotype 4 chronic hepatitis C. Liver Int 2012; 32(Suppl. 1): 146-50.
4. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228-37.
5. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon alpha-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005; 54: 858-66.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
7. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
8. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004; 99: 1733-7.
9. Fan X, Mao Q, Zhou D, et al. High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. Hepatology 2009; 50: 1765-72.
10. Al-Qahtani AA, Kessie G, Dela Cruz D, Al-Faleh FZ, Al-Ahdal MN. Quasispecies of genotype 4 of hepatitis C virus genomes in Saudi patients managed with interferon alfa and ribavirin therapy. Ann Saudi Med 2010; 30: 109-14.
11. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
12. Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE 2011; 6: e17232.
13. El-ShamyA, Shoji I, El-Akel W.et al. Sequence heterogeneity in NS5A of hepatitis c virus genotype 4 predicts clinical outcome of pegylated-interferon/ribavirin therapy. J Clin Microbiol, 2012; 50: 3886-92.
14. Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012; 84: 1217-23.
15. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010; 52: 501-7.
16. Dimitroulopoulos D, Elefsiniotis I, Pavlidis C., et al. European vs. Egyptian HCV-4 patients with elevated baseline HCV RNA, treated with PEG-IFN-α2a and ribavirin: the role of rapid and early virologic response. Hepat Mon 2010; 10: 193-8.
17. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007; 2007: 460-7.
18. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009; 58: 1662-9.
19. Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008; 28: 1112-9.
20. De Careaga BO. Predictive factors for response to treatment of chronic hepatitis C. Ann Hepatol 2006; 5(suppl. 1): S24-8.
21. Esmat G, El Akel W, Metwally M., et al. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss. Indian J Gastroenterol 2009; 28: 45-8.
22. El-Shazly Y, Rafeek M, Al-Swaff R. Effect of well controlled diabetes mellitus on sustained virologic response in chronic HCV genotype 4 infected patients. Journal of Diabetology 2012; 2: 3.
23. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010; 105: 1970-7.
24. Khattab M, Emad M, Abdelaleem A, et al. Pioglitazone improves virological response to peginterferon alpha-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int 2010; 30: 447-54.
25. Unicef country statistics. Available at www.unicef.org/infobycountry/egypt_statistics.
26. El-Zayadi A, Hepatitis B. Virus infection the Egyptian situation. Arab J Gastroenterol 2007; 8: 94-8.
27. Sterling RK, Sulkowski MS. Hepatitis C virus in the the setting of HIV OR Hepatitis B virus coinfection. Seminars Liver Dis 2004; 4: 1-12.
28. Sakuma I, Enomoto N, Kurosaki M, et al. Differntial effect of interferon on hepatitis C virus Ib quasispecies in the nonstructural protein 5A gene. J Infect Dis 1999; 180: 1001-9.
29. Brechot C, Thiers V, Kremsdorf D, et al. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatol 2001; 34: 194-203.
30. Elsharkawy A, Esmat G, Elraziky M, et al. HCV/Schistosomiasis coinfection: impact on fibrosis and response to pegylated interferon and Ribavirin therapy in chronic HCV patients. J Hepatol 2012; 56(Suppl): S61.
31. Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 2012; 19: 473-9.
32. Asselah T, Marcellin P. Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow. Liver Int 2012; 32(Suppl. 1): 88-102.
33. Manns MP, Foster GR, Rockstroh JK, et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007; 6: 991-1000.
34. Benhamou Y, Moussalli J, Ratziu V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naïve genotype 4 HCV patients. J Hepatol 2009; 50(Suppl): S6.
35. Seiwert SD, Andrews SW, Jiang Y, et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 2008; 52: 4432-41.
36. Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56: 1247-53.
37. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-9.
38. Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231-64.
39. McCaughan GW, Omata M, Amarapurkar D, et al. APASL Consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. APASL Hepatitis C Working Party, et al. J Gastroenterol Hepatol 2007;22 L615-33.
40. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
41. Khattab MA, Ferenci P, Hadziyannis SJ, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2011; 54: 1250-62.
42. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005; 43: 425-33.
43. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.
44. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.
45. Estrabaud E, Vidaud M, Marcellin P, Asselah T. Genomics and HCV infection: progression of fibrosis and treatment response. J Hepatol 2012; 57: 1110-25.